RG
LOGC

Redmile Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Redmile Group’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-749,026
Closed -$8.1M – 81
2019
Q3 		$8.1M Sell
749,026
-65,872
-8% -$705K 0.27% 56
2019
Q2 		$10.6M Sell
814,898
-94,889
-10% -$1.26M 0.3% 56
2019
Q1 		$8.99M Sell
909,787
-1,500
-0.2% -$14K 0.26% 57
2018
Q4 		$9.48M Buy
+911,287
New +$11M 0.38% 51

Other funds holding LOGC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Redmile Group's LOGC Position: Q4 2019 in Review

Redmile Group sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2019, closing a stake of 749,026 shares — an estimated $8.1M sold.

Redmile Group first reported a position in LOGC in Q4 2018 and held it in 4 quarters. The position peaked at $10.6M in Q2 2019. 44 funds tracked by Wall St. Rank hold LOGC as of Q4 2019.

  • Redmile Group reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Redmile Group sold 749,026 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $8.1M.
  • Redmile Group first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
  • Redmile Group's LogicBio Therapeutics, Inc. Common Stock position peaked at $10.6M in Q2 2019.
  • 44 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.